Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) regarding its 2019 annual meeting of stockholders held on December 30, 2019. The company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters related to the annual meeting.
Material Changes and Voting Results
The primary material event reported is the outcome of the stockholder vote. As of the record date (November 20, 2019), there were 37,649,000 shares outstanding. Approximately 85.79% of the voting power was represented at the meeting.
Election of Directors
Five directors were elected to serve until the next annual meeting. The voting results were as follows:
- Gregory H. Bailey: 25,809,876 votes for; 758,522 votes withheld.
- Annalisa Jenkins: 25,367,087 votes for; 1,201,311 votes withheld.
- John F. Mauldin: 26,245,604 votes for; 322,794 votes withheld.
- Michael H. May: 26,256,176 votes for; 312,222 votes withheld.
- Michael D. West: 26,278,179 votes for; 290,219 votes withheld.
There were 5,731,106 broker non-votes regarding the election of directors.
Ratification of Independent Accountants
Stockholders ratified the selection of OUM & Co. LLP as the independent registered public accountants for the 2019 fiscal year.
- For: 32,215,855 shares
- Against: 46,742 shares
- Abstain: 36,907 shares
There were no broker non-votes on this matter.
Guidance, Outlook, and Risks
The filing contains a standard forward-looking statements disclaimer, noting that actual results may differ materially from anticipated results due to factors detailed in the company's Form 10-K and Form 10-Q under "Risk Factors." No specific operational guidance or new risk factors were introduced in this document.
Investor Verification Checklist
- Verify the current status of the five newly elected directors and their tenure terms.
- Confirm the engagement of OUM & Co. LLP for the 2019 fiscal year audit.
- Review the company's most recent Form 10-K or 10-Q for financial performance data, as this 8-K does not contain financial statements.
- Check for any subsequent filings regarding the company's emerging growth company status or changes in accounting standards.